In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in the most recent decade. AutoSCT recipients diagnosed between 1992 and 2002 (n = 2737) were compared with those diagnosed between 2002 and 2010 (n = 3980). Patients diagnosed after 2002 had a significantly lower non-relapse mortality (NRM) and relapse incidence (RI) and a superior PFS and overall survival (OS). A total of 4210 patients diagnosed between 2002 and 2010 underwent either an autoSCT or an alloSCT as their first transplant procedure. Two-hundred and thirty patients received an alloSCT (myeloablative (MACalloSCT) n = 132, reduced intensity (RICalloSCT) n = 98). The 4-year NRM rates were 7%, 20% and 27% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year RI was 45%, 40% and 38% for autoSCT, RICalloSCT and MACalloSCT, respectively (NS). The 4-year PFS were 48%, 52% and 35% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year OS was 60%, 52% and 38% for autoSCT, RIC alloSCT and MACalloSCT, respectively. After adjustment for confounding factors NRM was significantly worse for patients undergoing alloSCT whilst there was no difference in the RI.
INTRODUCTION
The standard management of patients with diffuse large B-cell lymphoma (DLBCL) who fail first-line therapy comprises salvage chemotherapy followed by high-dose therapy and an autologous stem cell transplant (autoSCT). This treatment paradigm was established by the PARMA trial, which demonstrated a significant survival advantage for patients with chemosensitive disease who were randomized to high-dose therapy and an autoSCT. 1 Since the publication of this study, a number of developments have occurred in the treatment of DLBCL and in transplantation practice in general. A major advance has been the incorporation of rituximab into first-line chemoimmunotherapy leading to a significant improvement in survival. [2] [3] [4] As a consequence fewer patients relapse and require salvage therapy. Some investigators have also suggested than in the era of first-line chemoimmunotherapy the results of standard salvage therapy may have become less effective. 5, 6 The CORAL study suggested that patients who had received first-line chemoimmunotherapy and then relapsed within a year had a long-term disease-free survival of under 20% following standard salvage therapy and an autoSCT. 5 A similarly poor outcome has recently been described when either R-GDP or R-DHAP is employed as the salvage regimen before autoSCT. 6 In contrast to autoSCT, high-dose therapy and allogeneic stem cell transplant (alloSCT) has been rarely employed in DLBCL largely as a result of the significant toxicity reported in early studies of this modality. [7] [8] [9] [10] However, in studies comparing the outcome of autoSCT and alloSCT for aggressive non-Hodgkin's lymphoma the relapse rate following an allogeneic transplant was significantly lower suggesting a superior anti-lymphoma effect with this form of transplantation. 8, [11] [12] [13] Over the last decade there have been numerous developments in supportive care for alloSCT along with improvements in donor-selection tools and the development of novel reduced-intensity conditioning regimens. [14] [15] [16] [17] The outcomes of alloSCT for DLBCL in the most recent era may therefore be different to those described previously. 1 Given these developments in both the treatment of DLBCL and transplant practice there remains uncertainty as to the role of different SCT strategies for DLBCL in the current era. These changes in practice challenge the current paradigm that salvage induction and an autoSCT is the standard treatment for relapsed DLBCL. Specifically, it is unclear as to whether the outcomes of autoSCT have deteriorated in the era of immunochemotherapy where patients failing first-line treatment may represent a more unfavorable risk group. To address this question and to investigate if autoSCT can be outperformed by alloSCT if used as a first salvage transplant strategy in DLBCL, we have compared the outcome of autoSCT from a recent period with those from the pre-rituximab era as well as with allotransplants performed during the same time period.
PATIENTS AND METHODS

Data source
The EBMT is a voluntary organization comprising more than 600 transplant centers, mainly from Europe. Accreditation as a member center requires submission of minimal essential data (MED-A form) from all consecutive patients to a central registry in which patients may be identified by the diagnosis of underlying disease and type of stem cell transplant. MED-A data is updated annually. Informed consent for transplantation and data collection was obtained locally according to the regulations applicable at the time of transplantation. Since 1 January 2003, all transplant centers have been required to obtain written informed consent before data registration with the EBMT following the current version of the Helsinki Declaration.
Patient eligibility
Eligibility criteria for this study included the following: autoSCT, diagnosis of DLBCL between 2002 and 2009, age 18-65 years at SCT, first SCT procedure, relapsed disease or refractory disease. Cord blood and planned tandem transplants were excluded. All patients identified in the EBMT database fulfilling these criteria and having a minimum baseline data set available (age, sex, diagnosis, date of diagnosis, date of SCT, disease status at SCT, performance status (PS) at SCT and stem cell source) represented the study cohort. Controls were (1) those patients who fulfilled the same criteria but were diagnosed between 1992 and 2001; and (2) patients who were diagnosed between 2002 and 2009 and underwent an alloSCT as a first SCT, but otherwise met the criteria defining the study cohort.
Study definitions
DLBCL included cases reported locally as centroblastic, immunoblastic, mediastinal large B cell, intravascular large cell and primary effusion lymphoma. Status at transplantation was defined according to the EBMT definitions: complete response (CR) was defined as the disappearance of tumor masses and disease-related symptoms; partial response (PR) was considered when measurable lesions decreased by at least 50%; relapse was defined as the occurrence of new sites of disease after a CR lasting for 3 months or longer, whereas it was considered progression when CR had not been achieved. Monitoring of patients for relapse/progression post transplant was conducted according to the protocols of individual centers. Relapse or progression was considered to be 'chemosensitive' if at least PR was achieved following the last course of chemotherapy, otherwise it was considered as 'chemoresistant'. Good performance status was defined as Karnofsky score 480% or ECOG (Eastern Cooperative Oncology Group) score 0-1.
Outcomes measures
Endpoints analyzed were non-relapse mortality (NRM), relapse incidence (RI), PFS and overall survival (OS). OS was defined as the time from transplant to death from any cause. PFS was defined as the time from transplantation until disease relapse/progression or death from any cause. NRM included all causes of death with no disease progression/relapse occurring at any time after transplant.
Statistical methods
Patient characteristics were compared between groups using the Chi-square test or Fisher's exact test for categorical variables and the t-test or Mann-Whitney U-test for continuous variables. The probabilities of PFS and OS were estimated using the Kaplan-Meier estimator and compared by the log-rank test. The influence of transplant epoch and other potential risk factors on these outcomes was assessed using multivariate Cox proportional hazards regression analysis. NRM and RI were estimated using cumulative incidence estimates to account for competing risks and compared by Gray's test. The influence of transplant epoch and other potential risk factors for these outcomes were assessed using the Fine and Gray regression model.
To compare the outcomes of the study cohort with patients having undergone alloSCT in the same period, three different statistical methods were used as follows. First, one allogeneic transplant patient was matched to two autologous transplant patients using the following factors: age at SCT (±5 years), time from diagnosis to SCT (±5 months), gender and disease status at SCT. The influence of type of transplant on outcomes was estimated using stratified Cox proportional hazards regression model to account for matching. Second, an inverse probability weighting method was used to calculate an adjusted hazard ratio (HR) for each type of transplant and the effect on transplant outcomes. 18 Variables used to calculate the weightings were disease status at SCT, time from diagnosis to SCT, performance status at SCT, age, gender and year of diagnosis. Third, a standard Cox regression model was used to estimate the effect of type of transplant on outcome. Fine and Gray's modeling was employed to estimate the effect of type of SCT on RI and NRM. All variables were tested for a significant interaction with the main factor under study. The proportionality assumption of the Cox model was tested by adding a time-dependent covariate for each covariate factor. All analysis were performed using R (R: A Language and Environment for Statistical Computing, R Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2014, http://www.R-project.org). All P-values were two sided.
RESULTS
Influence of era on the outcome after autoSCT for DLBCL A total of 3980 patients were identified in the database who underwent autoSCT as a first transplant and were diagnosed with DLBCL between 2002 and 2009 (study cohort), and 2737 patients were identified for the 1992-2001 autoSCT control cohort. Patient and transplant characteristics are presented in Table 1 . The incidences of NRM at 100 days, 1 and 5 years after autoSCT were 5%, 7% and 9%, respectively, for patients diagnosed in 1992-2001 and 3%, 5% and 7%, respectively, for patients diagnosed Table 1. The NRM rates at 100 days and 4 years were 3%, 7% for autoSCT, 10% and 25% for MACalloSCT and 5% and 19% for RICalloSCT, respectively (Figure 3a) . The RI at 4 years was 50%, 47% and 53% for autoSCT, MACalloSCT and RICalloSCT, respectively (Figure 3a) . The 4-year PFS was 43%, 28% and 28% for autoSCT, MACalloSCT and RICalloSCT, respectively (Figure 3b ). The 4-year OS rates were 54%, 30% and 38% for autoSCT, MACalloSCT and RICalloSCT, respectively (Figure 3c ).
The outcome of the three forms of SCT after adjusting for confounders by three different statistical methods yielded consistent results as presented in Table 2 . Both MACalloSCT and RICalloSCT were associated with a significantly higher NRM when compared with autoSCT by standard Cox modeling stratified for age and gender. In addition to alloSCT, a chemorefractory status at SCT and a poor PS were significant predictors of an unfavorable NRM. In terms of OS and PFS, Cox modeling stratified for age, disease status at SCT, PS, and time interval from diagnosis to SCT demonstrated that MACalloSCT was significantly inferior to autoSCT, whilst for RICalloSCT the OS disadvantage was only of borderline significance and the PFS disadvantage non-significant. In contrast, there was no significant difference in the RI following the three types of SCTs. All results of Cox modeling were confirmed by both inverse probability weighting and pair-wise Abbreviations: BM = Bone marrow; CI = confidence interval; HR = hazard ratio; IQR = interquartile range; MismUD = mismatched unrelated donor; MUD = matched unrelated donor; NRM = non-relapse mortality; PB = peripheral blood; PS = performance status. Significant differences between the study group and other groups are indicated by the presence of a stated P-value.
matching except that the OS reduction associated with RICalloSCT was not significant in the matched pair analysis (Table 2) . Although a refractory disease status at SCT was associated with an increased RI and reduced survival after all three forms of SCT, there was no significant interaction between disease status and form of SCT.
Outcomes of stem cell transplantation according to disease status and interval from diagnosis For patients undergoing SCT in the period 2002-2009, the outcomes were analyzed according to the disease status at SCT (chemosensitive and chemorefractory) and the interval from diagnosis to SCT (418 months and o 18 months). For patients with chemosensitive disease the 4-year PFS following an autoSCT, MACalloSCT and RICalloSCT were 48%, 35% and 40%, and the 4-year OS were 60%, 38%, and 52%, respectively. In contrast, patients with chemorefractory disease had a 4-year PFS after autoSCT, MACalloSCT and RICalloSCT of 23%, 20% and 4%, and a 4-year OS of 30%, 21% and 7%, respectively. The worse outcome for patients with chemorefractory disease was due to the greater incidence of disease relapse following the SCT (4 year RI post autoSCT, MACalloSCT and RICalloSCT 69%, 59% and 80%, respectively). For patients undergoing a SCT more than 18 months after diagnosis the 4-year PFS following an autoSCT, MACalloSCT and RICalloSCT were 49%, 31% and 30%, respectively, while the 4-year OS were 61%, 31% and 42%, respectively. For patients undergoing a SCT within 18 months of diagnosis the 4-year PFS rates after an autoSCT, MACalloSCT and RICalloSCT were 37%, 25% and 28%, respectively and the 4-year OS rates were 46%, 37% and 31%, respectively.
DISCUSSION
The purpose of the current report was to describe the outcomes of both autoSCT and alloSCT for DLBCL as practiced in the most recent era. AutoSCT has been considered a standard of care for patients with aggressive lymphomas failing first-line therapy, and 40-50% of patients may be salvaged with this approach. 1, [19] [20] [21] However, recent observations have called into question the efficacy of this procedure in patients treated with first-line chemoimmunotherapy. 5, 6 To this end, the current study demonstrates that the outcome of patients who undergo an autoSCT has improved in the most recent time period when compared with the preceding decade. This resulted from a marginal reduction in both the NRM rate and the relapse rate, translating into superior PFS and OS. Although the MED-A tool does not capture information about the type of first-line therapy including rituximab exposure, it can be anticipated that the vast majority of patients with DLBCL diagnosed from 2002 onwards had received immunochemotherapy as this rapidly became a standard of care at the beginning of this century. In our analysis, exposure to rituximab before an autoSCT had no significant impact on the relapse rate or survival post transplant (data not shown). Therefore it may be concluded that in patients who manage to proceed to autoSCT after failure of immunochemotherapy, autoSCT is at least as effective as in patients having failed chemotherapy in the preceding decade. This supports previous observations that prior rituximab exposure did not negatively impact the outcome of patients undergoing autoSCT for DLBCL. 22, 23 As our database registers only patients who were actually transplanted, this observation does not exclude the possibility that the prognosis of DLBCL failing first-line immunochemotherapy may be worse than for those receiving chemotherapy alone. The current study also confirms previous findings that patients failing to respond to salvage induction and who have relapsed within a year of first-line therapy have a worse outcome following autoSCT. It is apparent that in the era of first-line immmunochemotherapy the outcome of standard salvage strategies and autoSCT for DLBCL is poor with only 20% of patients achieving long-term disease-free survival. 5, 6 Given the potential for superior disease control achieved by alloSCT we have studied the outcomes achieved with this modality. As anticipated, the number of alloSCT performed in this period was very low reflecting the prevailing treatment paradigms. It is not clear from this analysis why patients were selected for an alloSCT in place of the more standard autoSCT. Reasons for selection of an alloSCT over an autoSCT are varied and may include clinical trial recruitment, failure to collect autologous stem cells and the presence of poor risk features that were considered to predict a poor outcome with an autoSCT. There were differences in the pretransplant characteristics of patients undergoing the different forms of SCT therapy, which may partly reflect selection bias. Patients undergoing an alloSCT had more high-risk features including shorter interval from diagnosis to SCT, primary refractory disease, not in CR at SCT and chemorefractory disease at SCT. Moreover, additional poor-risk features and other hidden bias might have been present that were beyond the scope of the Med-A data set. In the current study, we are not able to determine these various criteria that were used in the selection of an alloSCT and there is clearly a lack of equipoise between patients undergoing an alloSCT an autoSCT.
Despite the improvements in transplant practice the toxicity of allogeneic transplantation in this setting remains significant with between 15 and 25% patients succumbing to NRM similar to that reported by others. 10, [14] [15] [16] [17] Although the mortality of alloSCT in the current era may appear lower than in the earlier reports, [7] [8] [9] it remains a major obstacle to the use of this procedure in these patients. The use of clinical risk scores that predict the anticipated NRM following an allogeneic SCT may be helpful to risk-stratify patients in this regard and should be studied in this setting. 24 A number of studies have demonstrated that the relapse rate following an alloSCT for aggressive non-Hodgkin's lymphoma is significantly lower than that following an autoSCT. [10] [11] [12] [13] Allogeneic SCT has also been shown to achieve long-term disease-free survival in patients that have failed a previous autoSCT. 25 Whether this relates to a graft vs lymphoma effect or the provision of a tumorfree graft remains to be clarified. 11 Overall, our data did not demonstrate that an alloSCT could achieve a lower relapse rate than an autoSCT. However, it should be noted that despite the higher prevalence of poor-risk features in patients undergoing an alloSCT, the relapse rate was similar to that after an autoSCT. Further, there was a plateau in the relapse curves following an alloSCT that was not apparent following an autoSCT. These two observations provide some indirect evidence that a graft vs lymphoma effect may be present in this disease. Given the limitations of comparison of retrospective data one would, however, require a prospective comparative study to determine which form of SCT was superior in this setting. A prospective phase-2 trial of intensive conditioning before alloSCT has recently demonstrated impressive efficacy and acceptable toxicity when T-cell depletion with antithymocyte globulin therapy is incorporated. 26 Patients with primary refractory and refractory relapse had a very poor outcome with either autoSCT or alloSCT in this study and particulary so for patients undergoing a RICalloSCT. It should be noted, however, that approximately 20% of patients with chemorefractory disease undergoing either an autoSCT or a MAC-alloSCT achieved durable disease-free survival. Patients with disease chemorefractory to salvage remain a priority for the development of alternative treatment strategies incorporating novel agents. Patients with chemosensitive relapsed DLBCL represent a heterogeneous population and will variably benefit from an autoSCT according to a number of factors such as positron emission tomography status pretransplant 27 and the secondary international prognostic index. 5, 6, 28 For patients predicted to be at high risk of failing an autoSCT a reduced intensity alloSCT may be considered and clinical studies in this setting are required.
In conclusion, autoSCT is an effective treatment for patients with relapsed DLBCL in the rituximab era and remains the standard of care at least in patients with chemosensitive disease. In contrast, this study fails to provide positive evidence that alloSCT is superior to autoSCT in any salvage setting in patients with DLBCL that have failed first-line chemoimmunotherapy. However, because of the numerous limitations this study does not exclude the possibility that there might be situations where an alloSCT may be superior to an autoSCT. Thus comparative studies are warranted. 
